Business Wire

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...

Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves

Q1 2026 Management View CEO Mitchell Steiner stated that Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs: enobosarm, a selective androgen receptor ...
Nasdaq

Belite Bio Announces Positive Interim Analysis for Phase 3 DRAGON Trial of Tinlarebant in Adolescent Stargardt Disease Patients

Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...
ascopubs.org

Primary analysis of a phase 1/2 study of LM-101: An anti-SIRPα antibody as a single agent in patients with advanced malignancies.

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Nasdaq

Sellas Life Sciences triggers interim analysis in Phase 3 REGAL trial

SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, ...
ascopubs.org

Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.

A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...